MARIA C CASTELLS
- Type
- Physician · Allopathic & Osteopathic Physicians / Allergy & Immunology
- Where
- GARDNER, MA
- NPI
- 1427039478
- Received
- $72,300 in 48 records, 2019 to 2025 ($65,050 general, $7,250 research)
- As principal investigator
- $2,770,654 of research payments to others in 147 records
- Source
- CMS Open Payments search ↗
By year
| Program year | Kind | Records | Amount |
|---|---|---|---|
| 2025 | General payment | 18 | $19,890 |
| 2025 | Research payment | 1 | $1,250 |
| 2024 | General payment | 10 | $13,560 |
| 2023 | General payment | 7 | $5,128 |
| 2023 | Research payment | 1 | $6,000 |
| 2022 | General payment | 5 | $16,542 |
| 2020 | General payment | 5 | $9,900 |
| 2019 | General payment | 1 | $27 |
By company
| Company | Records | Amount | Years |
|---|---|---|---|
| Blueprint Medicines Corporation | 24 | $43,832 | 2020–2025 |
| Bayer Healthcare Pharmaceuticals Inc. | 2 | $7,250 | 2023–2025 |
| TerSera Therapeutics LLC | 8 | $4,602 | 2025 |
| AstraZeneca UK Limited | 1 | $3,222 | 2024 |
| GENZYME CORPORATION | 1 | $3,140 | 2025 |
| SANOFI US SERVICES INC. | 3 | $2,455 | 2025 |
| Invivyd Inc | 2 | $1,830 | 2024–2025 |
| Mylan Inc. | 1 | $1,680 | 2022 |
| Cycle Pharmaceuticals Inc | 1 | $1,560 | 2025 |
| Eisai Inc. | 1 | $1,370 | 2025 |
| Daiichi Sankyo Inc. | 1 | $1,181 | 2022 |
| PFIZER INC. | 1 | $101 | 2024 |
| ARS Pharmaceuticals Operations, Inc. | 1 | $48 | 2025 |
| Shire North American Group Inc | 1 | $27 | 2019 |
By nature of payment
| Nature | Records | Amount |
|---|---|---|
| Honoraria | 10 | $31,443 |
| Consulting Fee | 13 | $25,199 |
| Research payment | 2 | $7,250 |
| Compensation for serving as faculty or as a speaker for a medical education program | 1 | $3,000 |
| Travel and Lodging | 7 | $2,810 |
| Compensation for services other than consulting, including serving as faculty or as a speaker at a v | 1 | $1,700 |
| Food and Beverage | 12 | $784 |
| Education | 2 | $112 |
Records
| Date | Company | Amount | Nature | Form | Product | Study | Year |
|---|---|---|---|---|---|---|---|
| 2025-12-10 | TerSera Therapeutics LLC | $952 | Consulting Fee | Cash or cash equivalent | Quzyttir Drug, Acute Care | 2025 | |
| 2025-12-03 | SANOFI US SERVICES INC. | $1,700 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | AYVAKIT Biological, Gastroenterology | 2025 | |
| 2025-11-25 | SANOFI US SERVICES INC. | $365 | Travel and Lodging | In-kind items and services | AYVAKIT Biological, Gastroenterology | 2025 | |
| 2025-11-18 | SANOFI US SERVICES INC. | $389 | Travel and Lodging | In-kind items and services | AYVAKIT Biological, Gastroenterology | 2025 | |
| 2025-11-08 | ARS Pharmaceuticals Operations, Inc. | $48 | Food and Beverage | In-kind items and services | NEFFY Drug, ALLERGY | 2025 | |
| 2025-09-16 | Cycle Pharmaceuticals Inc | $1,560 | Consulting Fee | Cash or cash equivalent | Cromolyn Sodium Drug, Pulmonary/Respiratory Diseases | 2025 | |
| 2025-08-07 | GENZYME CORPORATION | $3,140 | Consulting Fee | Cash or cash equivalent | AYVAKIT Biological, Gastroenterology | 2025 | |
| 2025-07-21 | TerSera Therapeutics LLC | $165 | Food and Beverage | In-kind items and services | Quzyttir Drug, Acute Care | 2025 | |
| 2025-07-02 | TerSera Therapeutics LLC | $60 | Education | In-kind items and services | Quzyttir Drug, Acute Care | 2025 | |
| 2025-07-02 | TerSera Therapeutics LLC | $52 | Education | In-kind items and services | Quzyttir Drug, Acute Care | 2025 | |
| 2025-06-30 | TerSera Therapeutics LLC | $3,000 | Compensation for serving as faculty or as a speaker for a medical education program | Cash or cash equivalent | Quzyttir Drug, Acute Care | 2025 | |
| 2025-06-30 | TerSera Therapeutics LLC | $165 | Travel and Lodging | Cash or cash equivalent | Quzyttir Drug, Acute Care | 2025 | |
| 2025-06-30 | TerSera Therapeutics LLC | $9 | Food and Beverage | Cash or cash equivalent | Quzyttir Drug, Acute Care | 2025 | |
| 2025-06-25 | Eisai Inc. | $1,370 | Consulting Fee | Cash or cash equivalent | Leqembi Drug, Neurology | 2025 | |
| 2025-06-13 | Blueprint Medicines Corporation | $3,140 | Honoraria | Cash or cash equivalent | AYVAKIT Drug, Oncology / Rare Diseases | 2025 | |
| 2025-06-13 | Blueprint Medicines Corporation | $2,355 | Honoraria | Cash or cash equivalent | AYVAKIT Drug, Oncology / Rare Diseases | 2025 | |
| 2025-05-13 | TerSera Therapeutics LLC | $196 | Travel and Lodging | In-kind items and services | Quzyttir Drug, Acute Care | 2025 | |
| 2025-03-31 | Bayer Healthcare Pharmaceuticals Inc. | $1,250 | Research payment | Cash or cash equivalent | Essure Device, Womens Health | Essure study 18894 | 2025 |
| 2025-02-06 | Invivyd Inc | $1,220 | Consulting Fee | Cash or cash equivalent | PEMGARDA Biological, INFECTIOUS DISEASE | 2025 | |
| 2024-12-06 | Blueprint Medicines Corporation | $87 | Food and Beverage | In-kind items and services | 2024 | ||
| 2024-10-30 | Invivyd Inc | $610 | Consulting Fee | Cash or cash equivalent | PEMGARDA Biological, INFECTIOUS DISEASE | 2024 | |
| 2024-10-23 | AstraZeneca UK Limited | $3,222 | Consulting Fee | Cash or cash equivalent | 2024 | ||
| 2024-09-19 | PFIZER INC. | $101 | Food and Beverage | In-kind items and services | CIBINQO Drug, Inflammation & Immunology | 2024 | |
| 2024-07-11 | Blueprint Medicines Corporation | $1,272 | Consulting Fee | Cash or cash equivalent | 2024 | ||
| 2024-06-06 | Blueprint Medicines Corporation | $5,457 | Consulting Fee | Cash or cash equivalent | 2024 | ||
| 2024-05-17 | Blueprint Medicines Corporation | $69 | Food and Beverage | In-kind items and services | AYVAKIT Drug, Oncology / Rare Diseases | 2024 | |
| 2024-04-29 | Blueprint Medicines Corporation | $51 | Food and Beverage | In-kind items and services | 2024 | ||
| 2024-04-29 | Blueprint Medicines Corporation | $38 | Food and Beverage | In-kind items and services | 2024 | ||
| 2024-02-21 | Blueprint Medicines Corporation | $2,650 | Honoraria | Cash or cash equivalent | 2024 | ||
| 2023-09-21 | Blueprint Medicines Corporation | $126 | Food and Beverage | In-kind items and services | 2023 | ||
| 2023-06-09 | Blueprint Medicines Corporation | $1,060 | Consulting Fee | Cash or cash equivalent | 2023 | ||
| 2023-06-01 | Blueprint Medicines Corporation | $22 | Food and Beverage | In-kind items and services | 2023 | ||
| 2023-02-14 | Bayer Healthcare Pharmaceuticals Inc. | $6,000 | Research payment | Cash or cash equivalent | Essure Device, Womens Health | Essure study 18894 "An open-label, non-randomized, prospective observational cohort study to assess post procedural outc | 2023 |
| 2023-01-27 | Blueprint Medicines Corporation | $2,226 | Honoraria | Cash or cash equivalent | 2023 | ||
| 2023-01-03 | Blueprint Medicines Corporation | $670 | Travel and Lodging | In-kind items and services | 2023 | ||
| 2023-01-03 | Blueprint Medicines Corporation | $595 | Travel and Lodging | In-kind items and services | 2023 | ||
| 2023-01-03 | Blueprint Medicines Corporation | $428 | Travel and Lodging | In-kind items and services | 2023 | ||
| 2022-08-23 | Daiichi Sankyo Inc. | $1,181 | Consulting Fee | Cash or cash equivalent | 2022 | ||
| 2022-08-18 | Blueprint Medicines Corporation | $34 | Food and Beverage | In-kind items and services | 2022 | ||
| 2022-05-26 | Blueprint Medicines Corporation | $1,272 | Honoraria | Cash or cash equivalent | 2022 | ||
| 2022-03-10 | Blueprint Medicines Corporation | $12,375 | Honoraria | Cash or cash equivalent | 2022 | ||
| 2022-03-01 | Mylan Inc. | $1,680 | Consulting Fee | Cash or cash equivalent | 2022 | ||
| 2020-12-01 | Blueprint Medicines Corporation | $1,485 | Honoraria | Cash or cash equivalent | AYVAKIT Drug, Oncology / Rare Diseases | 2020 | |
| 2020-10-30 | Blueprint Medicines Corporation | $1,980 | Honoraria | Cash or cash equivalent | 2020 | ||
| 2020-06-17 | Blueprint Medicines Corporation | $2,475 | Honoraria | Cash or cash equivalent | 2020 | ||
| 2020-05-29 | Blueprint Medicines Corporation | $1,485 | Honoraria | Cash or cash equivalent | AYVAKIT Drug, Oncology / Rare Diseases | 2020 | |
| 2020-05-26 | Blueprint Medicines Corporation | $2,475 | Consulting Fee | Cash or cash equivalent | AYVAKIT Drug, Oncology / Rare Diseases | 2020 | |
| 2019-02-21 | Shire North American Group Inc | $27 | Food and Beverage | In-kind items and services | CUVITRU Biological, IMMUNOLOGY | 2019 |
Research payments naming this person as principal investigator
| Date | Company | Paid to | Amount | Study | Year |
|---|---|---|---|---|---|
| 2025-12-19 | SANOFI US SERVICES INC. | Brigham And Womens Hospital | $17,955 | A Randomized, Double-Blind, Placebo-Controlled Phase 2/3 Study of BLU-263 in Indolent Systemic Mastocytosis | 2025 |
| 2025-12-19 | SANOFI US SERVICES INC. | Brigham And Womens Hospital | $910 | A Randomized, Double-Blind, Placebo-Controlled Phase 2/3 Study of BLU-263 in Indolent Systemic Mastocytosis | 2025 |
| 2025-12-18 | SANOFI US SERVICES INC. | Brigham And Womens Hospital | $3,409 | A 3-Part, Randomized, Double-Blind, Placebo-Controlled Phase 2 Study to Evaluate Safety and Efficacy of Avapritinib (BLU | 2025 |
| 2025-12-17 | SANOFI US SERVICES INC. | Brigham And Womens Hospital | $3,630 | A Randomized, Double-Blind, Placebo-Controlled Phase 2/3 Study of BLU-263 in Indolent Systemic Mastocytosis | 2025 |
| 2025-11-24 | SANOFI US SERVICES INC. | Brigham And Womens Hospital | $37,762 | A 3-Part, Randomized, Double-Blind, Placebo-Controlled Phase 2 Study to Evaluate Safety and Efficacy of Avapritinib (BLU | 2025 |
| 2025-11-19 | SANOFI US SERVICES INC. | Brigham And Womens Hospital | $2,176 | A Randomized, Double-Blind, Placebo-Controlled Phase 2/3 Study of BLU-263 in Indolent Systemic Mastocytosis | 2025 |
| 2025-11-03 | SANOFI US SERVICES INC. | Brigham And Womens Hospital | $5,614 | A Randomized, Double-Blind, Placebo-Controlled Phase 2/3 Study of BLU-263 in Indolent Systemic Mastocytosis | 2025 |
| 2025-10-30 | SANOFI US SERVICES INC. | Brigham And Womens Hospital | $9,340 | A 3-Part, Randomized, Double-Blind, Placebo-Controlled Phase 2 Study to Evaluate Safety and Efficacy of Avapritinib (BLU | 2025 |
| 2025-10-01 | SANOFI US SERVICES INC. | Brigham And Womens Hospital | $1,607 | A Randomized, Double-Blind, Placebo-Controlled Phase 2/3 Study of BLU-263 in Indolent Systemic Mastocytosis | 2025 |
| 2025-09-25 | SANOFI US SERVICES INC. | Brigham And Womens Hospital | $15,863 | A 3-Part, Randomized, Double-Blind, Placebo-Controlled Phase 2 Study to Evaluate Safety and Efficacy of Avapritinib (BLU | 2025 |
| 2025-09-04 | SANOFI US SERVICES INC. | Brigham And Womens Hospital | $16,194 | A 3-Part, Randomized, Double-Blind, Placebo-Controlled Phase 2 Study to Evaluate Safety and Efficacy of Avapritinib (BLU | 2025 |
| 2025-09-03 | SANOFI US SERVICES INC. | Brigham And Womens Hospital | $6,458 | A Randomized, Double-Blind, Placebo-Controlled Phase 2/3 Study of BLU-263 in Indolent Systemic Mastocytosis | 2025 |
| 2025-08-06 | SANOFI US SERVICES INC. | Brigham And Womens Hospital | $1,500 | A 3-Part, Randomized, Double-Blind, Placebo-Controlled Phase 2 Study to Evaluate Safety and Efficacy of Avapritinib (BLU | 2025 |
| 2025-08-06 | SANOFI US SERVICES INC. | Brigham And Womens Hospital | $195 | A 3-Part, Randomized, Double-Blind, Placebo-Controlled Phase 2 Study to Evaluate Safety and Efficacy of Avapritinib (BLU | 2025 |
| 2025-08-06 | SANOFI US SERVICES INC. | Brigham And Womens Hospital | $1,800 | A 3-Part, Randomized, Double-Blind, Placebo-Controlled Phase 2 Study to Evaluate Safety and Efficacy of Avapritinib (BLU | 2025 |
| 2025-08-06 | SANOFI US SERVICES INC. | Brigham And Womens Hospital | $39 | A 3-Part, Randomized, Double-Blind, Placebo-Controlled Phase 2 Study to Evaluate Safety and Efficacy of Avapritinib (BLU | 2025 |
| 2025-08-06 | SANOFI US SERVICES INC. | Brigham And Womens Hospital | $11,429 | A 3-Part, Randomized, Double-Blind, Placebo-Controlled Phase 2 Study to Evaluate Safety and Efficacy of Avapritinib (BLU | 2025 |
| 2025-07-24 | SANOFI US SERVICES INC. | Brigham And Womens Hospital | $11,730 | A 3-Part, Randomized, Double-Blind, Placebo-Controlled Phase 2 Study to Evaluate Safety and Efficacy of Avapritinib (BLU | 2025 |
| 2025-07-24 | SANOFI US SERVICES INC. | Brigham And Womens Hospital | $600 | A 3-Part, Randomized, Double-Blind, Placebo-Controlled Phase 2 Study to Evaluate Safety and Efficacy of Avapritinib (BLU | 2025 |
| 2025-07-18 | SANOFI US SERVICES INC. | Brigham And Womens Hospital | $1,487 | A 3-Part, Randomized, Double-Blind, Placebo-Controlled Phase 2 Study to Evaluate Safety and Efficacy of Avapritinib (BLU | 2025 |
| 2025-07-16 | Blueprint Medicines Corporation | Brigham And Womens Hospital | $78 | A Randomized, Double-Blind, Placebo-Controlled Phase 2/3 Study of BLU-263 in Indolent Systemic Mastocytosis | 2025 |
| 2025-07-16 | Blueprint Medicines Corporation | Brigham And Womens Hospital | $2,124 | A Randomized, Double-Blind, Placebo-Controlled Phase 2/3 Study of BLU-263 in Indolent Systemic Mastocytosis | 2025 |
| 2025-07-16 | Blueprint Medicines Corporation | Brigham And Womens Hospital | $39 | A Randomized, Double-Blind, Placebo-Controlled Phase 2/3 Study of BLU-263 in Indolent Systemic Mastocytosis | 2025 |
| 2025-06-20 | Blueprint Medicines Corporation | Brigham And Womens Hospital | $8,151 | A Randomized, Double-Blind, Placebo-Controlled Phase 2/3 Study of BLU-263 in Indolent Systemic Mastocytosis | 2025 |
| 2025-06-19 | Blueprint Medicines Corporation | Brigham And Womens Hospital | $5,080 | A 3-Part, Randomized, Double-Blind, Placebo-Controlled Phase 2 Study to Evaluate Safety and Efficacy of Avapritinib (BLU | 2025 |
| 2025-06-13 | Blueprint Medicines Corporation | Brigham And Womens Hospital | $25,273 | A 3-Part, Randomized, Double-Blind, Placebo-Controlled Phase 2 Study to Evaluate Safety and Efficacy of Avapritinib (BLU | 2025 |
| 2025-04-25 | Blueprint Medicines Corporation | Brigham And Womens Hospital | $900 | A Randomized, Double-Blind, Placebo-Controlled Phase 2/3 Study of BLU-263 in Indolent Systemic Mastocytosis | 2025 |
| 2025-04-24 | Blueprint Medicines Corporation | Brigham And Womens Hospital | $6,270 | A 3-Part, Randomized, Double-Blind, Placebo-Controlled Phase 2 Study to Evaluate Safety and Efficacy of Avapritinib (BLU | 2025 |
| 2025-04-17 | Blueprint Medicines Corporation | Brigham And Womens Hospital | $2,779 | A 3-Part, Randomized, Double-Blind, Placebo-Controlled Phase 2 Study to Evaluate Safety and Efficacy of Avapritinib (BLU | 2025 |
| 2025-04-17 | Blueprint Medicines Corporation | Brigham And Womens Hospital | $1,350 | A 3-Part, Randomized, Double-Blind, Placebo-Controlled Phase 2 Study to Evaluate Safety and Efficacy of Avapritinib (BLU | 2025 |
| 2025-03-27 | Blueprint Medicines Corporation | Brigham And Womens Hospital | $15,276 | A 3-Part, Randomized, Double-Blind, Placebo-Controlled Phase 2 Study to Evaluate Safety and Efficacy of Avapritinib (BLU | 2025 |
| 2025-03-12 | Blueprint Medicines Corporation | Brigham And Womens Hospital | $17,652 | A Randomized, Double-Blind, Placebo-Controlled Phase 2/3 Study of BLU-263 in Indolent Systemic Mastocytosis | 2025 |
| 2025-03-05 | Blueprint Medicines Corporation | Brigham And Womens Hospital | $351 | A Randomized, Double-Blind, Placebo-Controlled Phase 2/3 Study of BLU-263 in Indolent Systemic Mastocytosis | 2025 |
| 2025-03-05 | Blueprint Medicines Corporation | Brigham And Womens Hospital | $39 | A Randomized, Double-Blind, Placebo-Controlled Phase 2/3 Study of BLU-263 in Indolent Systemic Mastocytosis | 2025 |
| 2025-02-20 | Blueprint Medicines Corporation | Brigham And Womens Hospital | $56,739 | A 3-Part, Randomized, Double-Blind, Placebo-Controlled Phase 2 Study to Evaluate Safety and Efficacy of Avapritinib (BLU | 2025 |
| 2025-01-24 | Blueprint Medicines Corporation | Brigham And Womens Hospital | $750 | A Randomized, Double-Blind, Placebo-Controlled Phase 2/3 Study of BLU-263 in Indolent Systemic Mastocytosis | 2025 |
| 2025-01-24 | Blueprint Medicines Corporation | Brigham And Womens Hospital | $600 | A Randomized, Double-Blind, Placebo-Controlled Phase 2/3 Study of BLU-263 in Indolent Systemic Mastocytosis | 2025 |
| 2025-01-24 | Blueprint Medicines Corporation | Brigham And Womens Hospital | $7,590 | A Randomized, Double-Blind, Placebo-Controlled Phase 2/3 Study of BLU-263 in Indolent Systemic Mastocytosis | 2025 |
| 2025-01-09 | Blueprint Medicines Corporation | Brigham And Womens Hospital | $300 | A 3-Part, Randomized, Double-Blind, Placebo-Controlled Phase 2 Study to Evaluate Safety and Efficacy of Avapritinib (BLU | 2025 |
| 2025-01-09 | Blueprint Medicines Corporation | Brigham And Womens Hospital | $900 | A 3-Part, Randomized, Double-Blind, Placebo-Controlled Phase 2 Study to Evaluate Safety and Efficacy of Avapritinib (BLU | 2025 |
| 2025-01-09 | Blueprint Medicines Corporation | Brigham And Womens Hospital | $600 | A 3-Part, Randomized, Double-Blind, Placebo-Controlled Phase 2 Study to Evaluate Safety and Efficacy of Avapritinib (BLU | 2025 |
| 2025-01-03 | Blueprint Medicines Corporation | Brigham And Womens Hospital | $10,961 | A 3-Part, Randomized, Double-Blind, Placebo-Controlled Phase 2 Study to Evaluate Safety and Efficacy of Avapritinib (BLU | 2025 |
| 2024-12-20 | Blueprint Medicines Corporation | BRIGHAM AND WOMENS HOSPITAL | $9,179 | A Randomized, Double-Blind, Placebo-Controlled Phase 2/3 Study of BLU-263 in Indolent Systemic Mastocytosis | 2024 |
| 2024-12-06 | Blueprint Medicines Corporation | BRIGHAM AND WOMENS HOSPITAL | $17,300 | A Randomized, Double-Blind, Placebo-Controlled Phase 2/3 Study of BLU-263 in Indolent Systemic Mastocytosis | 2024 |
| 2024-11-15 | Blueprint Medicines Corporation | BRIGHAM AND WOMENS HOSPITAL | $7,590 | A Randomized, Double-Blind, Placebo-Controlled Phase 2/3 Study of BLU-263 in Indolent Systemic Mastocytosis | 2024 |
| 2024-10-10 | Blueprint Medicines Corporation | BRIGHAM AND WOMENS HOSPITAL | $9,340 | A 3-Part, Randomized, Double-Blind, Placebo-Controlled Phase 2 Study to Evaluate Safety and Efficacy of Avapritinib (BLU | 2024 |
| 2024-10-04 | Blueprint Medicines Corporation | BRIGHAM AND WOMENS HOSPITAL | $64,185 | A 3-Part, Randomized, Double-Blind, Placebo-Controlled Phase 2 Study to Evaluate Safety and Efficacy of Avapritinib (BLU | 2024 |
| 2024-10-04 | Blueprint Medicines Corporation | BRIGHAM AND WOMENS HOSPITAL | $2,094 | A 3-Part, Randomized, Double-Blind, Placebo-Controlled Phase 2 Study to Evaluate Safety and Efficacy of Avapritinib (BLU | 2024 |
| 2024-10-02 | Blueprint Medicines Corporation | BRIGHAM AND WOMENS HOSPITAL | $41,221 | A Randomized, Double-Blind, Placebo-Controlled Phase 2/3 Study of BLU-263 in Indolent Systemic Mastocytosis | 2024 |
| 2024-09-25 | Blueprint Medicines Corporation | BRIGHAM AND WOMENS HOSPITAL | $300 | A Randomized, Double-Blind, Placebo-Controlled Phase 2/3 Study of BLU-263 in Indolent Systemic Mastocytosis | 2024 |
| 2024-09-25 | Blueprint Medicines Corporation | BRIGHAM AND WOMENS HOSPITAL | $127,847 | A Randomized, Double-Blind, Placebo-Controlled Phase 2/3 Study of BLU-263 in Indolent Systemic Mastocytosis | 2024 |
| 2024-09-04 | Blueprint Medicines Corporation | BRIGHAM AND WOMENS HOSPITAL | $1,240 | A Randomized, Double-Blind, Placebo-Controlled Phase 2/3 Study of BLU-263 in Indolent Systemic Mastocytosis | 2024 |
| 2024-09-04 | Blueprint Medicines Corporation | BRIGHAM AND WOMENS HOSPITAL | $4,000 | A Randomized, Double-Blind, Placebo-Controlled Phase 2/3 Study of BLU-263 in Indolent Systemic Mastocytosis | 2024 |
| 2024-09-04 | Blueprint Medicines Corporation | BRIGHAM AND WOMENS HOSPITAL | $1,628 | A Randomized, Double-Blind, Placebo-Controlled Phase 2/3 Study of BLU-263 in Indolent Systemic Mastocytosis | 2024 |
| 2024-09-04 | Blueprint Medicines Corporation | BRIGHAM AND WOMENS HOSPITAL | $4,500 | A Randomized, Double-Blind, Placebo-Controlled Phase 2/3 Study of BLU-263 in Indolent Systemic Mastocytosis | 2024 |
| 2024-09-04 | Blueprint Medicines Corporation | BRIGHAM AND WOMENS HOSPITAL | $1,500 | A Randomized, Double-Blind, Placebo-Controlled Phase 2/3 Study of BLU-263 in Indolent Systemic Mastocytosis | 2024 |
| 2024-09-04 | Blueprint Medicines Corporation | BRIGHAM AND WOMENS HOSPITAL | $10,000 | A Randomized, Double-Blind, Placebo-Controlled Phase 2/3 Study of BLU-263 in Indolent Systemic Mastocytosis | 2024 |
| 2024-09-04 | Blueprint Medicines Corporation | BRIGHAM AND WOMENS HOSPITAL | $5,000 | A Randomized, Double-Blind, Placebo-Controlled Phase 2/3 Study of BLU-263 in Indolent Systemic Mastocytosis | 2024 |
| 2024-08-22 | Blueprint Medicines Corporation | BRIGHAM AND WOMENS HOSPITAL | $1,350 | A 3-Part, Randomized, Double-Blind, Placebo-Controlled Phase 2 Study to Evaluate Safety and Efficacy of Avapritinib (BLU | 2024 |
| 2024-08-21 | Blueprint Medicines Corporation | BRIGHAM AND WOMENS HOSPITAL | $600 | A Randomized, Double-Blind, Placebo-Controlled Phase 2/3 Study of BLU-263 in Indolent Systemic Mastocytosis | 2024 |
| 2024-08-21 | Blueprint Medicines Corporation | BRIGHAM AND WOMENS HOSPITAL | $97 | A Randomized, Double-Blind, Placebo-Controlled Phase 2/3 Study of BLU-263 in Indolent Systemic Mastocytosis | 2024 |
| 2024-08-21 | Blueprint Medicines Corporation | BRIGHAM AND WOMENS HOSPITAL | $900 | A Randomized, Double-Blind, Placebo-Controlled Phase 2/3 Study of BLU-263 in Indolent Systemic Mastocytosis | 2024 |
| 2024-08-21 | Blueprint Medicines Corporation | BRIGHAM AND WOMENS HOSPITAL | $1,820 | A Randomized, Double-Blind, Placebo-Controlled Phase 2/3 Study of BLU-263 in Indolent Systemic Mastocytosis | 2024 |
| 2024-08-21 | Blueprint Medicines Corporation | BRIGHAM AND WOMENS HOSPITAL | $2,000 | A Randomized, Double-Blind, Placebo-Controlled Phase 2/3 Study of BLU-263 in Indolent Systemic Mastocytosis | 2024 |
| 2024-08-21 | Blueprint Medicines Corporation | BRIGHAM AND WOMENS HOSPITAL | $97 | A Randomized, Double-Blind, Placebo-Controlled Phase 2/3 Study of BLU-263 in Indolent Systemic Mastocytosis | 2024 |
| 2024-05-30 | Blueprint Medicines Corporation | BRIGHAM AND WOMENS HOSPITAL | $13,080 | A 3-Part, Randomized, Double-Blind, Placebo-Controlled Phase 2 Study to Evaluate Safety and Efficacy of Avapritinib (BLU | 2024 |
| 2024-05-22 | Blueprint Medicines Corporation | BRIGHAM AND WOMENS HOSPITAL | $600 | A Randomized, Double-Blind, Placebo-Controlled Phase 2/3 Study of BLU-263 in Indolent Systemic Mastocytosis | 2024 |
| 2024-05-01 | Blueprint Medicines Corporation | BRIGHAM AND WOMENS HOSPITAL | $600 | A Randomized, Double-Blind, Placebo-Controlled Phase 2/3 Study of BLU-263 in Indolent Systemic Mastocytosis | 2024 |
| 2024-04-25 | Blueprint Medicines Corporation | BRIGHAM AND WOMENS HOSPITAL | $16,194 | A 3-Part, Randomized, Double-Blind, Placebo-Controlled Phase 2 Study to Evaluate Safety and Efficacy of Avapritinib (BLU | 2024 |
| 2024-04-17 | Blueprint Medicines Corporation | BRIGHAM AND WOMENS HOSPITAL | $68,249 | A Randomized, Double-Blind, Placebo-Controlled Phase 2/3 Study of BLU-263 in Indolent Systemic Mastocytosis | 2024 |
| 2024-03-27 | Blueprint Medicines Corporation | BRIGHAM AND WOMENS HOSPITAL | $6,558 | A 3-Part, Randomized, Double-Blind, Placebo-Controlled Phase 2 Study to Evaluate Safety and Efficacy of Avapritinib (BLU | 2024 |
| 2024-03-07 | Blueprint Medicines Corporation | BRIGHAM AND WOMENS HOSPITAL | $9,706 | A 3-Part, Randomized, Double-Blind, Placebo-Controlled Phase 2 Study to Evaluate Safety and Efficacy of Avapritinib (BLU | 2024 |
| 2024-02-15 | Blueprint Medicines Corporation | BRIGHAM AND WOMENS HOSPITAL | $16,264 | A 3-Part, Randomized, Double-Blind, Placebo-Controlled Phase 2 Study to Evaluate Safety and Efficacy of Avapritinib (BLU | 2024 |
| 2024-01-25 | Blueprint Medicines Corporation | BRIGHAM AND WOMENS HOSPITAL | $9,340 | A 3-Part, Randomized, Double-Blind, Placebo-Controlled Phase 2 Study to Evaluate Safety and Efficacy of Avapritinib (BLU | 2024 |
| 2024-01-11 | Blueprint Medicines Corporation | BRIGHAM AND WOMENS HOSPITAL | $6,297 | A 3-Part, Randomized, Double-Blind, Placebo-Controlled Phase 2 Study to Evaluate Safety and Efficacy of Avapritinib (BLU | 2024 |
| 2023-12-27 | Blueprint Medicines Corporation | Brigham And Womens Hospital | $3,148 | A 3-Part, Randomized, Double-Blind, Placebo-Controlled Phase 2 Study to Evaluate Safety and Efficacy of Avapritinib (BLU | 2023 |
| 2023-12-14 | Blueprint Medicines Corporation | Brigham And Womens Hospital | $3,218 | A 3-Part, Randomized, Double-Blind, Placebo-Controlled Phase 2 Study to Evaluate Safety and Efficacy of Avapritinib (BLU | 2023 |
| 2023-12-13 | Blueprint Medicines Corporation | Brigham And Womens Hospital | $600 | A Randomized, Double-Blind, Placebo-Controlled Phase 2/3 Study of BLU-263 in Indolent Systemic Mastocytosis | 2023 |
| 2023-12-13 | Blueprint Medicines Corporation | Brigham And Womens Hospital | $600 | A Randomized, Double-Blind, Placebo-Controlled Phase 2/3 Study of BLU-263 in Indolent Systemic Mastocytosis | 2023 |
| 2023-12-08 | Blueprint Medicines Corporation | Brigham And Womens Hospital | $600 | A Randomized, Double-Blind, Placebo-Controlled Phase 2/3 Study of BLU-263 in Indolent Systemic Mastocytosis | 2023 |
| 2023-11-29 | Blueprint Medicines Corporation | Brigham And Womens Hospital | $31,465 | A 3-Part, Randomized, Double-Blind, Placebo-Controlled Phase 2 Study to Evaluate Safety and Efficacy of Avapritinib (BLU | 2023 |
| 2023-10-20 | Blueprint Medicines Corporation | Brigham And Womens Hospital | $1,200 | A Randomized, Double-Blind, Placebo-Controlled Phase 2/3 Study of BLU-263 in Indolent Systemic Mastocytosis | 2023 |
| 2023-10-19 | Blueprint Medicines Corporation | Brigham And Womens Hospital | $9,671 | A 3-Part, Randomized, Double-Blind, Placebo-Controlled Phase 2 Study to Evaluate Safety and Efficacy of Avapritinib (BLU | 2023 |
| 2023-10-05 | Blueprint Medicines Corporation | Brigham And Womens Hospital | $6,558 | A 3-Part, Randomized, Double-Blind, Placebo-Controlled Phase 2 Study to Evaluate Safety and Efficacy of Avapritinib (BLU | 2023 |
| 2023-09-07 | Blueprint Medicines Corporation | Brigham And Womens Hospital | $22,752 | A 3-Part, Randomized, Double-Blind, Placebo-Controlled Phase 2 Study to Evaluate Safety and Efficacy of Avapritinib (BLU | 2023 |
| 2023-08-03 | Blueprint Medicines Corporation | Brigham And Womens Hospital | $21,934 | A 3-Part, Randomized, Double-Blind, Placebo-Controlled Phase 2 Study to Evaluate Safety and Efficacy of Avapritinib (BLU | 2023 |
| 2023-07-06 | Blueprint Medicines Corporation | Brigham And Womens Hospital | $13,376 | A 3-Part, Randomized, Double-Blind, Placebo-Controlled Phase 2 Study to Evaluate Safety and Efficacy of Avapritinib (BLU | 2023 |
| 2023-06-15 | Blueprint Medicines Corporation | Brigham And Womens Hospital | $25,901 | A 3-Part, Randomized, Double-Blind, Placebo-Controlled Phase 2 Study to Evaluate Safety and Efficacy of Avapritinib (BLU | 2023 |
| 2023-05-04 | Blueprint Medicines Corporation | Brigham And Womens Hospital | $3,113 | A 3-Part, Randomized, Double-Blind, Placebo-Controlled Phase 2 Study to Evaluate Safety and Efficacy of Avapritinib (BLU | 2023 |
| 2023-04-21 | Blueprint Medicines Corporation | Brigham And Womens Hospital | $6,993 | A Randomized, Double-Blind, Placebo-Controlled Phase 2/3 Study of BLU-263 in Indolent Systemic Mastocytosis | 2023 |
| 2023-04-20 | Blueprint Medicines Corporation | Brigham And Womens Hospital | $15,689 | A 3-Part, Randomized, Double-Blind, Placebo-Controlled Phase 2 Study to Evaluate Safety and Efficacy of Avapritinib (BLU | 2023 |
| 2023-04-06 | Blueprint Medicines Corporation | Brigham And Womens Hospital | $19,082 | A 3-Part, Randomized, Double-Blind, Placebo-Controlled Phase 2 Study to Evaluate Safety and Efficacy of Avapritinib (BLU | 2023 |
| 2023-04-05 | Blueprint Medicines Corporation | Brigham And Womens Hospital | $69,189 | A Randomized, Double-Blind, Placebo-Controlled Phase 2/3 Study of BLU-263 in Indolent Systemic Mastocytosis | 2023 |
| 2023-03-03 | Blueprint Medicines Corporation | Brigham And Womens Hospital | $11,073 | A 3-Part, Randomized, Double-Blind, Placebo-Controlled Phase 2 Study to Evaluate Safety and Efficacy of Avapritinib (BLU | 2023 |
| 2023-02-02 | Blueprint Medicines Corporation | Brigham And Womens Hospital | $18,891 | A 3-Part, Randomized, Double-Blind, Placebo-Controlled Phase 2 Study to Evaluate Safety and Efficacy of Avapritinib (BLU | 2023 |
| 2023-01-05 | Blueprint Medicines Corporation | Brigham And Womens Hospital | $30,064 | A 3-Part, Randomized, Double-Blind, Placebo-Controlled Phase 2 Study to Evaluate Safety and Efficacy of Avapritinib (BLU | 2023 |
| 2022-12-08 | Blueprint Medicines Corporation | Brigham And Womens Hospital | $2,893 | A 3-Part, Randomized, Double-Blind, Placebo-Controlled Phase 2 Study to Evaluate Safety and Efficacy of Avapritinib (BLU | 2022 |
| 2022-11-17 | Blueprint Medicines Corporation | Brigham And Womens Hospital | $6,262 | A 3-Part, Randomized, Double-Blind, Placebo-Controlled Phase 2 Study to Evaluate Safety and Efficacy of Avapritinib (BLU | 2022 |
| 2022-11-16 | Blueprint Medicines Corporation | Brigham And Womens Hospital | $20,992 | A Randomized, Double-Blind, Placebo-Controlled Phase 2/3 Study of BLU-263 in Indolent Systemic Mastocytosis | 2022 |
| 2022-10-27 | Blueprint Medicines Corporation | Brigham And Womens Hospital | $52,163 | A 3-Part, Randomized, Double-Blind, Placebo-Controlled Phase 2 Study to Evaluate Safety and Efficacy of Avapritinib (BLU | 2022 |
CMS Open Payments: payments and transfers of value that drug and medical device makers and group purchasing organizations report to Medicare, program years 2019 on, as published by CMS (general, research and ownership records; refreshed by CMS each June and January). Links to other records on this site are by name (and state) only.
The area Census
County outline, the place (blue), the tract (orange) and the ZIP center (dot).
In Gardner, MA, county Worcester County, MA, state Massachusetts; placed by its city name.
| Measure | Place (city or town) Gardner, MA | County Worcester County, MA | State Massachusetts |
|---|---|---|---|
| Population B01003 | 21,148 | 867,788 | 7,044,056 |
| Population, 2020 census P1 | 21,287 | 862,111 | 7,029,917 |
| Median age B01002 | 43.7 | 40.2 | 40.0 |
| Under 18 B01001 | 18.3% | 20.6% | 19.4% |
| 65 and over B01001 | 19.6% | 17.0% | 17.9% |
| Households B11001 | 8,940 | 335,826 | 2,785,042 |
| Foreign born B05002 | 7.9% | 14.5% | 18.0% |
| Median household income B19013 | $67,518 | $95,939 | $103,960 |
| Median family income B19113 | $80,168 | $119,408 | $131,675 |
| Per capita income B19301 | $37,215 | $48,914 | $57,897 |
| Poverty rate B17001 | 13.7% | 10.3% | 10.0% |
| Unemployment rate B23025 | 7.0% | 5.3% | 5.2% |
| Civilian labor force B23025 | 10,355 | 471,761 | 3,911,446 |
| Mean commute (minutes) B08013 | 30.5 | 29.2 | 29.1 |
| Bachelor's degree or higher B15003 | 23.8% | 39.7% | 47.3% |
| Housing units B25001 | 9,488 | 355,185 | 3,030,406 |
| Owner-occupied B25003 | 58.9% | 65.8% | 62.5% |
| Renters B25003 | 41.1% | 34.2% | 37.5% |
| Median home value B25077 | $301,600 | $423,700 | $562,100 |
| Median gross rent B25064 | $1,109 | $1,426 | $1,762 |
| White, not Hispanic B03002 | 77.6% | 70.3% | 66.6% |
| Black B03002 | 4.0% | 4.8% | 6.4% |
| Hispanic or Latino B03002 | 10.7% | 13.7% | 13.3% |
| Asian B03002 | 2.4% | 5.3% | 7.3% |
| American Indian and Alaska Native B03002 | 0.1% | 0.1% | 0.1% |
Economy now FRED unemployment 4.3% in Sep 2026 (4.6% a year earlier); per capita personal income $98,700 in 2025, up 27% in five years (+2.3% after inflation); the state; Source: FRED, Federal Reserve Bank of St. Louis.
Data: IPUMS NHGIS (ACS 2020-2024 and the 2020 census); each figure links to its table for that area at data.census.gov. Records are placed by ZIP code and city name, not street address. More: everything FURP has in Gardner, MA.
Comments